18 completed, 2 active not recruiting, 2 unknown, 1 no longer available. 16 Phase 2, 9 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 13, Active not recruiting 2, Unknown 1 |
| Phase 1 | 9 | Completed 8, Unknown 1 |
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
Follow ibudilast: new trials by email Literature Review of ibudilast trials Research Report on ibudilast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Ibudilast, Pentoxifylline, Placebo - Long COVID, Post COVID Condition | Phase 2 / Phase 3 | Completed | University Health Network, Toronto | 460 | 2023-05-31 | 2026-02-23 |
| Ibudilast for Treating Alcohol Use Disorder Ibudilast, Medical management, Placebo - Alcohol Use Disorder (AUD), Alcoholism | Phase 2 | Active not recruiting | University of Pennsylvania | 50 | 2023-01-14 | 2026-06-03 |
| Regeneration in Cervical Degenerative Myelopathy Ibudilast, Cervical decompressive surgery, Matching placebo - Myelopathy, Spinal Cord Diseases | Phase 3 | Unknown | Cambridge University Hospitals NHS Foundation Trust | 400 | 2021-12-22 | 2022-01-13 |
| Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS Ibudilast, Placebo - Pneumonia, Viral | Phase 2 | Completed | MediciNova | 34 | 2021-01-11 | 2024-10-30 |
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS MN-166, placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Active not recruiting | MediciNova | 234 | 2020-05-28 | 2026-03-06 |
| Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers MN-166 - Healthy Volunteers | Phase 1 | Completed | MediciNova | 12 | 2019-06-24 | 2020-07-15 |
| Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users Ibudilast, Placebo Oral Tablet - Methamphetamine-dependence | Phase 2 | Completed | VA Office of Research and Development | 176 | 2019-05-01 | 2026-02-02 |
| Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma MN-166, Temozolomide - Glioblastoma, Recurrent Glioblastoma | Phase 1 / Phase 2 | Completed | MediciNova | 64 | 2018-12-29 | 2025-05-21 |
| Ibudilast for the Treatment of Alcohol Use Disorder Ibudilast, Placebo oral capsule - Alcohol Use Disorder | Phase 2 | Completed | University of California, Los Angeles | 102 | 2018-10-01 | 2024-11-27 |
| Ibudilast and Withdrawal-Related Dysphoria Ibudilast, Placebo - Alcohol Use Disorder | Phase 2 | Completed | University of California, Los Angeles | 52 | 2018-07-16 | 2021-10-07 |
| Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers MN-166 - Healthy Volunteers | Phase 1 | Completed | MediciNova | 28 | 2018-04-11 | 2019-05-31 |
| A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) ibudilast, Ibudilast - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Completed | MediciNova | 35 | 2016-05-06 | 2024-09-24 |
| Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) Placebo (for MN-166), MN-166, riluzole - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | MediciNova | 70 | 2014-09-01 | 2021-11-05 |
| Development of Ibudilast for Alcohol Use Disorder Ibudilast, Matched placebo - Alcohol Use Disorders | Phase 1 | Completed | University of California, Los Angeles | 24 | 2013-12-01 | 2016-02-23 |
| Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis ibudilast, Placebo oral capsule - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Phase 2 | Completed | MediciNova | 255 | 2013-11-01 | 2020-07-28 |
| Trial of Ibudilast for Methamphetamine Dependence Ibudilast, Placebo - Methamphetamine Dependence, HIV Infection | Phase 2 | Completed | University of California, Los Angeles | 125 | 2013-07-01 | 2019-01-30 |
| Ibudilast in the Treatment of Patients With Chronic Migraine. Ibudilast, Placebo - Migraine Headache | Phase 1 | Completed | Parisa Gazerani | 33 | 2013-06-01 | 2015-12-29 |
| Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers MN-166 (50 mg) First, Placebo First - Opioid Abuse, Opioid Dependence | Phase 2 | Completed | New York State Psychiatric Institute | 28 | 2012-11-01 | 2017-08-17 |
| Ibudilast in the Treatment of Medication Overuse Headache Ibudilast, Placebo - Medication Overuse Headache | Phase 1 / Phase 2 | Unknown | University of Adelaide | 40 | 2011-04-01 | 2013-02-06 |
| Safety Interaction Trial Ibudilast and Methamphetamine Ibudilast 20mg, Ibudilast 50mg, Placebo oral tablet - Methamphetamine-dependence, Substance Abuse | Phase 1 | Completed | University of California, Los Angeles | 11 | 2011-01-01 | 2023-05-15 |
Showing 20 of 23. Sign in to see all of them.
Alcoholism (4) · Amyotrophic Lateral Sclerosis (3) · Opioid-Related Disorders (2) · Agnosia (1) · COVID-19 (1) · Diabetic Neuropathies (1) · Glioblastoma (1) · HIV Infections (1) · Headache Disorders, Secondary (1) · Migraine Disorders (1) · Multiple Sclerosis, Chronic Progressive (1) · Neuroinflammatory Diseases (1) · Pain (1) · Pneumonia (1) · Pneumonia, Viral (1)
MediciNova (8) · University of California, Los Angeles (5) · New York State Psychiatric Institute (2) · Avigen (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Mayo Clinic (1) · Parisa Gazerani (1) · University Health Network, Toronto (1) · University of Adelaide (1) · University of Pennsylvania (1) · VA Office of Research and Development (1)
United States (18) · Australia (3) · Canada (2) · United Kingdom (1)
Kazuko Matsuda, MD PhD MPH (2) · Sandra D Comer, PhD (2) · Angela M Cheung, MD,PhD (1) · Benjamin Davies, MD (1) · Benjamin R Brooks, M.D. (1) · Bjorn E Oskarsson, MD (1) · David P Walling, PhD (1) · George Tomlinson, PhD (1) · Henry R Kranzler, MD (1) · Keith Heinzerling, MD (1) · Lara A Ray, PhD (1) · Lara A. Ray, PhD (1) · Lara Ray, PhD (1) · Milky Kohno, PhD (1) · Parisa Gazerani, PharmD, PhD (1)
PMID 25175864, PMID 25975386, PMID 29794557, PMID 30157388, PMID 32912290, PMID 33054533, PMID 34016561, PMID 34585396, PMID 34816762, PMID 36008843, PMID 36102596, PMID 37537928, PMID 39217272, PMID 40305022, PMID 41342004, PMID 41509523, PMID 41603979, PMID 41928198
P50DA009236 (2), 2017 (1), R01AA026190 (1), R01DA029804 (1), R01DA035054 (1), R21AA022214 (1), U01NS082329 (1), U01NS136022 (1)